+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Pegfilgrastim Market by Application (Chemotherapy-Induced Neutropenia, Peripheral Blood Stem Cell Mobilization), Product Type (On-Body Injector, Prefilled Pen, Prefilled Syringe), Origin, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Pegfilgrastim Market by Application (Chemotherapy-Induced Neutropenia, Peripheral Blood Stem Cell Mobilization), Product Type (On-Body Injector, Prefilled Pen, Prefilled Syringe), Origin, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Pegfilgrastim Market by Application (Chemotherapy-Induced Neutropenia, Peripheral Blood Stem Cell Mobilization), Product Type (On-Body Injector, Prefilled Pen, Prefilled Syringe), Origin, End User, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 193 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6158848
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The landscape of neutropenia management has been fundamentally reshaped by the introduction of pegfilgrastim, a long-acting granulocyte colony-stimulating factor analog that extends the interval between administrations while maintaining efficacy in reducing the risk of infection among patients undergoing myelosuppressive chemotherapy. Over the past decade, this biologic therapy has evolved from a niche intervention into a cornerstone of supportive oncology care, reflecting both advances in protein engineering and an increasing emphasis on patient-centric treatment modalities. This report offers a concise yet rich overview of the market forces, clinical trends, and regulatory developments influencing pegfilgrastim adoption, while highlighting the strategic imperatives for stakeholders across the value chain.

By examining the drivers of growth-from biosimilar competition to delivery system innovation-and identifying the challenges posed by pricing pressures and supply chain complexity, this introduction sets the stage for a detailed exploration of the shifts poised to define the next phase of market expansion. It seeks to inform decision-makers about the critical factors that will determine competitive advantage, patient access, and long-term sustainability in this dynamic therapeutic arena.

Emerging Catalysts Transforming the Pegfilgrastim Market

Scientific breakthroughs and regulatory milestones have converged to propel pegfilgrastim into a new era of clinical application and commercial potential. The development of on-body injector systems has eliminated the need for repeated clinic visits, enabling patients to self-administer the therapy with minimal professional supervision and fostering greater adherence. Concurrently, the emergence of next-generation biosimilars has intensified competitive dynamics, prompting both originator and biosimilar manufacturers to seek differentiation through novel delivery formats, enhanced stability profiles, and expanded labeling across additional cancer indications.

Moreover, regulatory authorities worldwide have crafted frameworks that streamline biosimilar approvals while upholding rigorous standards for interchangeability, creating an environment where cost-effective alternatives can rapidly gain market share. Investments in real-world evidence studies and patient support programs have further solidified pegfilgrastim’s role in value-based care models. As these elements converge, the market is witnessing a transformative realignment that emphasizes convenience, affordability, and clinical effectiveness.

Assessing the 2025 United States Tariff Effects on Supply Dynamics

The introduction of new tariffs by the United States in early 2025 has generated material implications for pegfilgrastim supply chains and pricing strategies. Tariff levies on key active pharmaceutical ingredients and biologic components have led to a recalibration of sourcing decisions, with manufacturers evaluating alternative suppliers and on-shoring certain production steps to mitigate cost escalations. The increased import duties have also accelerated discussions around formulary placements, as payers reassess cost structures and seek to leverage group purchasing organizations for better pricing terms.

In response to these headwinds, several stakeholders have adopted more agile supply chain models, characterized by dual sourcing and inventory buffering. Meanwhile, collaborative agreements between contract development and manufacturing organizations and biosimilar producers are emerging to distribute tariff risk and ensure uninterrupted product availability. These strategic adaptations underscore the industry’s resilience in the face of shifting trade policies, even as organizations brace for potential further adjustments in international trade agreements.

Unveiling Comprehensive Pegfilgrastim Market Segmentation Insights

Dissecting the pegfilgrastim market through the lens of application reveals a bifurcation between chemotherapy-induced neutropenia and peripheral blood stem cell mobilization, with the former segment subdivided into breast cancer, colorectal cancer, and lung cancer treatment settings. Patterns of utilization differ markedly across these oncology indications, reflecting variations in chemotherapy regimens and associated neutropenic risk profiles. On the delivery front, product formats encompass on-body injectors, prefilled pens, and prefilled syringes, each offering a distinct combination of convenience, precision dosing, and patient preference.

Origin-based analysis distinguishes between biosimilar and originator products, where biosimilar offerings from companies like Pfizer and Sandoz have rapidly gained traction by leveraging established manufacturing networks and competitive pricing. Within the hospital and clinic channels, end-user segmentation highlights the contrast between high-throughput infusion centers and outpatient oncology practices, while further differentiation between private and public hospitals illuminates disparities in procurement processes and budgetary constraints. Distribution pathways span hospital pharmacies, online pharmacies, and retail pharmacies, with the latter category subdivided into chain and independent operators that differ in their purchasing power and patient outreach strategies. Together, these layered segmentation insights provide a nuanced understanding of where value is created and how strategic focus areas can be prioritized for maximum impact.

Regional Dynamics Shaping Global Pegfilgrastim Adoption

Geographic analysis of pegfilgrastim adoption uncovers distinct regional dynamics. In the Americas, the United States continues to dominate volume and revenue metrics, driven by robust oncology research ecosystems, high per capita healthcare spending, and well-established reimbursement frameworks. Canada and Latin American markets are in various stages of embracing biosimilar introductions, with local regulatory harmonization facilitating market entry.

Within Europe, Middle East & Africa, Western European countries lead in biosimilar uptake, benefiting from centralized tender processes and national healthcare systems that emphasize cost containment. Meanwhile, emerging markets in the Middle East and Africa present untapped potential, constrained by infrastructure limitations and budgetary pressures. In the Asia-Pacific region, rapid urbanization and expanding oncology service networks in China, Japan, and Australia are fueling demand, even as price sensitivity and variable regulatory landscapes require manufacturers to adopt flexible market entry strategies. These geographical nuances underscore the importance of tailored commercial approaches and strategic partnerships to maximize regional penetration.

Profiling Leading Players Driving Pegfilgrastim Innovation

The competitive landscape of pegfilgrastim is characterized by a mix of originator biologic leaders and agile biosimilar developers. Originator innovators continue to invest in enhanced delivery devices and patient support programs, while biosimilar entrants leverage leaner cost structures to offer price-competitive alternatives. Strategic alliances between multinational pharmaceutical companies and contract manufacturing organizations have become increasingly common, aimed at accelerating time to market and ensuring scalable production capabilities.

Several key players have also diversified their portfolios by pursuing label expansions into stem cell mobilization and exploring combination therapies that integrate pegfilgrastim with novel immuno-oncology agents. In parallel, cross-border collaborations and distribution agreements are being forged to overcome tariff-driven supply chain challenges and extend reach into underserved markets. These developments reflect an industry in flux, where speed to market, cost efficiency, and differentiated value propositions will determine leadership positions.

Actionable Strategies for Enhanced Market Positioning

Industry leaders should prioritize investments in next-generation delivery platforms, refining on-body injector designs to further enhance patient autonomy and adherence. It is imperative to deepen collaborations with healthcare providers and payers to demonstrate real-world effectiveness and secure favorable formulary placements. Organizations must also adopt flexible supply chain architectures, incorporating dual sourcing and localized manufacturing to mitigate the impact of tariff fluctuations and geopolitical uncertainties.

Expanding the biosimilar pipeline through mergers, acquisitions, or in-licensing can create synchronized economies of scale, unlocking cost advantages that can be passed on to health systems. Furthermore, forging strategic partnerships in emerging regions will accelerate market penetration and build capacity in settings where access remains limited. By aligning research, commercial, and operational strategies under a unified framework, industry stakeholders can achieve sustainable growth and deliver superior patient outcomes.

Robust Methodology Underpinning Our Research Rigor

Our research methodology integrates a rigorous blend of primary and secondary data collection to ensure comprehensive market coverage and analytical precision. Primary research was conducted through in-depth interviews with key opinion leaders, oncologists, pharmacists, and supply chain experts, providing firsthand perspectives on clinical adoption trends and operational challenges. Secondary data sources included published scientific literature, regulatory filings, industry reports, and proprietary databases, which were systematically cross-verified to maintain the highest standards of accuracy.

Quantitative analysis employed advanced statistical techniques to evaluate historical trends and identify correlation patterns, while qualitative insights were synthesized to contextualize market drivers, barriers, and strategic imperatives. All findings underwent meticulous validation through internal peer review and external expert feedback, ensuring that conclusions reflect both current realities and future trajectories in the pegfilgrastim landscape.

Synthesis of Key Findings and Strategic Implications

This executive summary has distilled the critical factors shaping the pegfilgrastim market, from transformative delivery innovations and regulatory shifts to tariff-induced supply chain adaptations. Detailed segmentation analysis and regional perspectives further illuminate where growth opportunities are most pronounced, while competitive profiling highlights the strategic moves driving market evolution. The recommendations provided serve as a blueprint for industry leaders seeking to navigate uncertainty, optimize resource allocation, and foster sustainable value creation.

As the healthcare ecosystem continues to embrace biologic therapies and cost-effective biosimilars, the ability to anticipate market inflection points and respond with agility will be paramount. By leveraging the insights and strategic frameworks presented herein, stakeholders can position themselves at the forefront of pegfilgrastim development and commercialization, ultimately improving patient access and outcomes.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Application
    • Chemotherapy-Induced Neutropenia
      • Breast Cancer
      • Colorectal Cancer
      • Lung Cancer
    • Peripheral Blood Stem Cell Mobilization
  • Product Type
    • On-Body Injector
    • Prefilled Pen
    • Prefilled Syringe
  • Origin
    • Biosimilar
      • Pfizer
      • Sandoz
    • Originator
  • End User
    • Clinics
    • Hospitals
      • Private Hospitals
      • Public Hospitals
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
      • Chain Pharmacies
      • Independent Pharmacies
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Alvotech
  • Amgen Inc.
  • Apotex Inc.
  • Biocon Biologics Limited
  • CinnaGen Inc.
  • Coherus BioSciences, Inc.
  • CuraTeQ Biologics Pvt. Ltd. by Aurobindo Pharma Ltd.
  • Dr. Reddy’s Laboratories Ltd.
  • Fresenius Kabi USA, LLC
  • Gennova Biopharmaceuticals Limited.
  • Intas Pharmaceuticals Ltd.
  • Mundipharma International Limited
  • Mylan N.V. by Viatris Inc.
  • Pfizer Inc.
  • Qilu Pharmaceutical Co., Ltd.
  • Sandoz Inc. by Novartis AG
  • Stada Arzneimittel AG

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Expansion of personalized dosing algorithms leveraging AI to tailor pegfilgrastim therapy in neutropenia management
5.2. Integration of digital health platforms to monitor pegfilgrastim adherence and improve patient outcomes
5.3. Rising adoption of biosimilar pegfilgrastim driving pricing competition and market access expansion
5.4. Increasing investment in on-body injector technology to enhance pegfilgrastim patient compliance and outcomes
5.5. Strategic partnerships between biotech firms and contract manufacturers boosting global pegfilgrastim supply chain resilience
5.6. Emergence of wearable device integration with pegfilgrastim therapy enabling real-time adherence monitoring and data analytics
5.7. Regulatory approvals of next-generation pegfilgrastim formulations accelerating biosafety and dosing optimization initiatives
5.8. Value-based contracting models incentivizing reduced pegfilgrastim costs through outcome-driven reimbursement agreements
5.9. Rising emphasis on real-world evidence studies to demonstrate pegfilgrastim safety and cost-effectiveness in practice
5.10. Innovations in prefilled syringe and on-body delivery systems reshaping pegfilgrastim patient experience
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Pegfilgrastim Market, by Application
8.1. Introduction
8.2. Chemotherapy-Induced Neutropenia
8.2.1. Breast Cancer
8.2.2. Colorectal Cancer
8.2.3. Lung Cancer
8.3. Peripheral Blood Stem Cell Mobilization
9. Pegfilgrastim Market, by Product Type
9.1. Introduction
9.2. On-Body Injector
9.3. Prefilled Pen
9.4. Prefilled Syringe
10. Pegfilgrastim Market, by Origin
10.1. Introduction
10.2. Biosimilar
10.2.1. Pfizer
10.2.2. Sandoz
10.3. Originator
11. Pegfilgrastim Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Hospitals
11.3.1. Private Hospitals
11.3.2. Public Hospitals
12. Pegfilgrastim Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Online Pharmacies
12.4. Retail Pharmacies
12.4.1. Chain Pharmacies
12.4.2. Independent Pharmacies
13. Americas Pegfilgrastim Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Argentina
13.5. Mexico
13.6. Brazil
14. Europe, Middle East & Africa Pegfilgrastim Market
14.1. Introduction
14.2. Nigeria
14.3. France
14.4. Switzerland
14.5. Denmark
14.6. Italy
14.7. Finland
14.8. Turkey
14.9. South Africa
14.10. Sweden
14.11. United Kingdom
14.12. Netherlands
14.13. United Arab Emirates
14.14. Norway
14.15. Poland
14.16. Spain
14.17. Germany
14.18. Qatar
14.19. Egypt
14.20. Saudi Arabia
14.21. Israel
14.22. Russia
15. Asia-Pacific Pegfilgrastim Market
15.1. Introduction
15.2. Vietnam
15.3. Japan
15.4. India
15.5. Indonesia
15.6. Malaysia
15.7. Australia
15.8. South Korea
15.9. Taiwan
15.10. China
15.11. Thailand
15.12. Philippines
15.13. Singapore
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Alvotech
16.3.2. Amgen Inc.
16.3.3. Apotex Inc.
16.3.4. Biocon Biologics Limited
16.3.5. CinnaGen Inc.
16.3.6. Coherus BioSciences, Inc.
16.3.7. CuraTeQ Biologics Pvt. Ltd. by Aurobindo Pharma Ltd.
16.3.8. Dr. Reddy’s Laboratories Ltd.
16.3.9. Fresenius Kabi USA, LLC
16.3.10. Gennova Biopharmaceuticals Limited.
16.3.11. Intas Pharmaceuticals Ltd.
16.3.12. Mundipharma International Limited
16.3.13. Mylan N.V. by Viatris Inc.
16.3.14. Pfizer Inc.
16.3.15. Qilu Pharmaceutical Co., Ltd.
16.3.16. Sandoz Inc. by Novartis AG
16.3.17. Stada Arzneimittel AG
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. PEGFILGRASTIM MARKET MULTI-CURRENCY
FIGURE 2. PEGFILGRASTIM MARKET MULTI-LANGUAGE
FIGURE 3. PEGFILGRASTIM MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL PEGFILGRASTIM MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL PEGFILGRASTIM MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL PEGFILGRASTIM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PEGFILGRASTIM MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PEGFILGRASTIM MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PEGFILGRASTIM MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PEGFILGRASTIM MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PEGFILGRASTIM MARKET SIZE, BY ORIGIN, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PEGFILGRASTIM MARKET SIZE, BY ORIGIN, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PEGFILGRASTIM MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PEGFILGRASTIM MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL PEGFILGRASTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL PEGFILGRASTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS PEGFILGRASTIM MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS PEGFILGRASTIM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES PEGFILGRASTIM MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES PEGFILGRASTIM MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PEGFILGRASTIM MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PEGFILGRASTIM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC PEGFILGRASTIM MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC PEGFILGRASTIM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. PEGFILGRASTIM MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. PEGFILGRASTIM MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. PEGFILGRASTIM MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PEGFILGRASTIM MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PEGFILGRASTIM MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL PEGFILGRASTIM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL PEGFILGRASTIM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL PEGFILGRASTIM MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL PEGFILGRASTIM MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL PEGFILGRASTIM MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL PEGFILGRASTIM MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL PEGFILGRASTIM MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL PEGFILGRASTIM MARKET SIZE, BY PERIPHERAL BLOOD STEM CELL MOBILIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL PEGFILGRASTIM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL PEGFILGRASTIM MARKET SIZE, BY ON-BODY INJECTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL PEGFILGRASTIM MARKET SIZE, BY PREFILLED PEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL PEGFILGRASTIM MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL PEGFILGRASTIM MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL PEGFILGRASTIM MARKET SIZE, BY BIOSIMILAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL PEGFILGRASTIM MARKET SIZE, BY PFIZER, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL PEGFILGRASTIM MARKET SIZE, BY SANDOZ, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL PEGFILGRASTIM MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL PEGFILGRASTIM MARKET SIZE, BY ORIGINATOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL PEGFILGRASTIM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL PEGFILGRASTIM MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL PEGFILGRASTIM MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL PEGFILGRASTIM MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL PEGFILGRASTIM MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL PEGFILGRASTIM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL PEGFILGRASTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL PEGFILGRASTIM MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL PEGFILGRASTIM MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL PEGFILGRASTIM MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL PEGFILGRASTIM MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL PEGFILGRASTIM MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL PEGFILGRASTIM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS PEGFILGRASTIM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS PEGFILGRASTIM MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS PEGFILGRASTIM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS PEGFILGRASTIM MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS PEGFILGRASTIM MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS PEGFILGRASTIM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS PEGFILGRASTIM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS PEGFILGRASTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS PEGFILGRASTIM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS PEGFILGRASTIM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES PEGFILGRASTIM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES PEGFILGRASTIM MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES PEGFILGRASTIM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES PEGFILGRASTIM MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES PEGFILGRASTIM MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES PEGFILGRASTIM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES PEGFILGRASTIM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES PEGFILGRASTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES PEGFILGRASTIM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES PEGFILGRASTIM MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 56. CANADA PEGFILGRASTIM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 57. CANADA PEGFILGRASTIM MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 58. CANADA PEGFILGRASTIM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 59. CANADA PEGFILGRASTIM MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 60. CANADA PEGFILGRASTIM MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 61. CANADA PEGFILGRASTIM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 62. CANADA PEGFILGRASTIM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 63. CANADA PEGFILGRASTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 64. CANADA PEGFILGRASTIM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA PEGFILGRASTIM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA PEGFILGRASTIM MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA PEGFILGRASTIM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA PEGFILGRASTIM MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA PEGFILGRASTIM MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA PEGFILGRASTIM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA PEGFILGRASTIM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA PEGFILGRASTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA PEGFILGRASTIM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 74. MEXICO PEGFILGRASTIM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 75. MEXICO PEGFILGRASTIM MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 76. MEXICO PEGFILGRASTIM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 77. MEXICO PEGFILGRASTIM MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 78. MEXICO PEGFILGRASTIM MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 79. MEXICO PEGFILGRASTIM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. MEXICO PEGFILGRASTIM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 81. MEXICO PEGFILGRASTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 82. MEXICO PEGFILGRASTIM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL PEGFILGRASTIM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL PEGFILGRASTIM MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL PEGFILGRASTIM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL PEGFILGRASTIM MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL PEGFILGRASTIM MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL PEGFILGRASTIM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL PEGFILGRASTIM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL PEGFILGRASTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL PEGFILGRASTIM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA PEGFILGRASTIM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA PEGFILGRASTIM MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA PEGFILGRASTIM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA PEGFILGRASTIM MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA PEGFILGRASTIM MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA PEGFILGRASTIM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA PEGFILGRASTIM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA PEGFILGRASTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA PEGFILGRASTIM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA PEGFILGRASTIM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 102. NIGERIA PEGFILGRASTIM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 103. NIGERIA PEGFILGRASTIM MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 104. NIGERIA PEGFILGRASTIM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 105. NIGERIA PEGFILGRASTIM MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 106. NIGERIA PEGFILGRASTIM MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 107. NIGERIA PEGFILGRASTIM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 108. NIGERIA PEGFILGRASTIM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 109. NIGERIA PEGFILGRASTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. NIGERIA PEGFILGRASTIM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 111. FRANCE PEGFILGRASTIM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 112. FRANCE PEGFILGRASTIM MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 113. FRANCE PEGFILGRASTIM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 114. FRANCE PEGFILGRASTIM MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 115. FRANCE PEGFILGRASTIM MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 116. FRANCE PEGFILGRASTIM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. FRANCE PEGFILGRASTIM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 118. FRANCE PEGFILGRASTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 119. FRANCE PEGFILGRASTIM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 120. SWITZERLAND PEGFILGRASTIM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 121. SWITZERLAND PEGFILGRASTIM MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 122. SWITZERLAND PEGFILGRASTIM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 123. SWITZERLAND PEGFILGRASTIM MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 124. SWITZERLAND PEGFILGRASTIM MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 125. SWITZERLAND PEGFILGRASTIM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 126. SWITZERLAND PEGFILGRASTIM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 127. SWITZERLAND PEGFILGRASTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 128. SWITZERLAND PEGFILGRASTIM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 129. DENMARK PEGFILGRASTIM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 130. DENMARK PEGFILGRASTIM MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 131. DENMARK PEGFILGRASTIM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 132. DENMARK PEGFILGRASTIM MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 133. DENMARK PEGFILGRASTIM MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 134. DENMARK PEGFILGRASTIM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 135. DENMARK PEGFILGRASTIM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 136. DENMARK PEGFILGRASTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. DENMARK PEGFILGRASTIM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 138. ITALY PEGFILGRASTIM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 139. ITALY PEGFILGRASTIM MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 140. ITALY PEGFILGRASTIM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 141. ITALY PEGFILGRASTIM MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 142. ITALY PEGFILGRASTIM MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 143. ITALY PEGFILGRASTIM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. ITALY PEGFILGRASTIM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 145. ITALY PEGFILGRASTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. ITALY PEGFILGRASTIM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 147. FINLAND PEGFILGRASTIM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 148. FINLAND PEGFILGRASTIM MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 149. FINLAND PEGFILGRASTIM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 150. FINLAND PEGFILGRASTIM MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 151. FINLAND PEGFILGRASTIM MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 152. FINLAND PEGFILGRASTIM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 153. FINLAND PEGFILGRASTIM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 154. FINLAND PEGFILGRASTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 155. FINLAND PEGFILGRASTIM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 156. TURKEY PEGFILGRASTIM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 157. TURKEY PEGFILGRASTIM MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 158. TURKEY PEGFILGRASTIM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 159. TURKEY PEGFILGRASTIM MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 160. TURKEY PEGFILGRASTIM MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 161. TURKEY PEGFILGRASTIM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 162. TURKEY PEGFILGRASTIM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 163. TURKEY PEGFILGRASTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 164. TURKEY PEGFILGRASTIM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA PEGFILGRASTIM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA PEGFILGRASTIM MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA PEGFILGRASTIM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 168. SOUTH AFRICA PEGFILGRASTIM MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 169. SOUTH AFRICA PEGFILGRASTIM MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 170. SOUTH AFRICA PEGFILGRASTIM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. SOUTH AFRICA PEGFILGRASTIM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 172. SOUTH AFRICA PEGFILGRASTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 173. SOUTH AFRICA PEGFILGRASTIM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 174. SWEDEN PEGFILGRASTIM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 175. SWEDEN PEGFILGRASTIM MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 176. SWEDEN PEGFILGRASTIM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 177. SWEDEN PEGFILGRASTIM MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 178. SWEDEN PEGFILGRASTIM MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 179. SWEDEN PEGFILGRASTIM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 180. SWEDEN PEGFILGRASTIM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 181. SWEDEN PEGFILGRASTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. SWEDEN PEGFILGRASTIM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM PEGFILGRASTIM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 184. UNITED KINGDOM PEGFILGRASTIM MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM PEGFILGRASTIM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 186. UNITED KINGDOM PEGFILGRASTIM MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM PEGFILGRASTIM MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 188. UNITED KINGDOM PEGFILGRASTIM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM PEGFILGRASTIM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 190. UNITED KINGDOM PEGFILGRASTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM PEGFILGRASTIM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 192. NETHERLANDS PEGFILGRASTIM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 193. NETHERLANDS PEGFILGRASTIM MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 194. NETHERLANDS PEGFILGRASTIM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 195. NETHERLANDS PEGFILGRASTIM MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 196. NETHERLANDS PEGFILGRASTIM MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 197. NETHERLANDS PEGFILGRASTIM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. NETHERLANDS PEGFILGRASTIM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 199. NETHERLANDS PEGFILGRASTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS PEGFILGRASTIM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 201. UNITED ARAB EMIRATES PEGFILGRASTIM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 202. UNITED ARAB EMIRATES PEGFILGRASTIM MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 203. UNITED ARAB EMIRATES PEGFILGRASTIM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 204. UNITED ARAB EMIRATES PEGFILGRASTIM MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 205. UNITED ARAB EMIRATES PEGFILGRASTIM MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 206. UNITED ARAB EMIRATES PEGFILGRASTIM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 207. UNITED ARAB EMIRATES PEGFILGRASTIM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 208. UNITED ARAB EMIRATES PEGFILGRASTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 209. UNITED ARAB EMIRATES PEGFILGRASTIM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 210. NORWAY PEGFILGRASTIM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 211. NORWAY PEGFILGRASTIM MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 212. NORWAY PEGFILGRASTIM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 213. NORWAY PEGFILGRASTIM MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 214. NORWAY PEGFILGRASTIM MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 215. NORWAY PEGFILGRASTIM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 216. NORWAY PEGFILGRASTIM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 217. NORWAY PEGFILGRASTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 218. NORWAY PEGFILGRASTIM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 219. POLAND PEGFILGRASTIM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 220. POLAND PEGFILGRASTIM MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 221. POLAND PEGFILGRASTIM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 222. POLAND PEGFILGRASTIM MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 223. POLAND PEGFILGRASTIM MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 224. POLAND PEGFILGRASTIM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 225. POLAND PEGFILGRASTIM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 226. POLAND PEGFILGRASTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 227. POLAND PEGFILGRASTIM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 228. SPAIN PEGFILGRASTIM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 229. SPAIN PEGFILGRASTIM MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 230. SPAIN PEGFILGRASTIM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 231. SPAIN PEGFILGRASTIM MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 232. SPAIN PEGFILGRASTIM MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 233. SPAIN PEGFILGRASTIM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 234. SPAIN PEGFILGRASTIM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 235. SPAIN PEGFILGRASTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 236. SPAIN PEGFILGRASTIM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 237. GERMANY PEGFILGRASTIM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 238. GERMANY PEGFILGRASTIM MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 239. GERMANY PEGFILGRASTIM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 240. GERMANY PEGFILGRASTIM MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 241. GERMANY PEGFILGRASTIM MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 242. GERMANY PEGFILGRASTIM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. GERMANY PEGFILGRASTIM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 244. GERMANY PEGFILGRASTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 245. GERMANY PEGFILGRASTIM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 246. QATAR PEGFILGRASTIM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 247. QATAR PEGFILGRASTIM MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 248. QATAR PEGFILGRASTIM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 249. QATAR PEGFILGRASTIM MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 250. QATAR PEGFILGRASTIM MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 251. QATAR PEGFILGRASTIM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 252. QATAR PEGFILGRASTIM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 253. QATAR PEGFILGRASTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 254. QATAR PEGFILGRASTIM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 255. EGYPT PEGFILGRASTIM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 256. EGYPT PEGFILGRASTIM MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 257. EGYPT PEGFILGRASTIM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 258. EGYPT PEGFILGRASTIM MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 259. EGYPT PEGFILGRASTIM MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 260. EGYPT PEGFILGRASTIM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 261. EGYPT PEGFILGRASTIM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 262. EGYPT PEGFILGRASTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 263. EGYPT PEGFILGRASTIM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 264. SAUDI ARABIA PEGFILGRASTIM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 265. SAUDI ARABIA PEGFILGRASTIM MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 266. SAUDI ARABIA PEGFILGRASTIM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 267. SAUDI ARABIA PEGFILGRASTIM MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 268. SAUDI ARABIA PEGFILGRASTIM MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA PEGFILGRASTIM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 270. SAUDI ARABIA PEGFILGRASTIM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA PEGFILGRASTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 272. SAUDI ARABIA PEGFILGRASTIM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 273. ISRAEL PEGFILGRASTIM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 274. ISRAEL PEGFILGRASTIM MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 275. ISRAEL PEGFILGRASTIM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 276. ISRAEL PEGFILGRASTIM MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 277. ISRAEL PEGFILGRASTIM MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 278. ISRAEL PEGFILGRASTIM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 279. ISRAEL PEGFILGRASTIM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 280. ISRAEL PEGFILGRASTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 281. ISRAEL PEGFILGRASTIM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 282. RUSSIA PEGFILGRASTIM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 283. RUSSIA PEGFILGRASTIM MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 284. RUSSIA PEGFILGRASTIM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 285. RUSSIA PEGFILGRASTIM MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 286. RUSSIA PEGFILGRASTIM MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 287. RUSSIA PEGFILGRASTIM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 288. RUSSIA PEGFILGRASTIM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 289. RUSSIA PEGFILGRASTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 290. RUSSIA PEGFILGRASTIM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 291. ASIA-PACIFIC PEGFILGRASTIM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 292. ASIA-PACIFIC PEGFILGRASTIM MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 293. ASIA-PACIFIC PEGFILGRASTIM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 294. ASIA-PACIFIC PEGFILGRASTIM MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 295. ASIA-PACIFIC PEGFILGRASTIM MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 296. ASIA-PACIFIC PEGFILGRASTIM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 297. ASIA-PACIFIC PEGFILGRASTIM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 298. ASIA-PACIFIC PEGFILGRASTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 299. ASIA-PACIFIC PEGFILGRASTIM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 300. ASIA-PACIFIC PEGFILGRASTIM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 301. VIETNAM PEGFILGRASTIM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 302. VIETNAM PEGFILGRASTIM MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 303. VIETNAM PEGFILGRASTIM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 304. VIETNAM PEGFILGRASTIM MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 305. VIETNAM PEGFILGRASTIM MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 306. VIETNAM PEGFILGRASTIM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 307. VIETNAM PEGFILGRASTIM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 308. VIETNAM PEGFILGRASTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 309. VIETNAM PEGFILGRASTIM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 310. JAPAN PEGFILGRASTIM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 311. JAPAN PEGFILGRASTIM MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 312. JAPAN PEGFILGRASTIM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 313. JAPAN PEGFILGRASTIM MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 314. JAPAN PEGFILGRASTIM MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 315. JAPAN PEGFILGRASTIM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 316. JAPAN PEGFILGRASTIM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 317. JAPAN PEGFILGRASTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 318. JAPAN PEGFILGRASTIM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 319. INDIA PEGFILGRASTIM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 320. INDIA PEGFILGRASTIM MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 321. INDIA PEGFILGRASTIM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 322. INDIA PEGFILGRASTIM MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 323. INDIA PEGFILGRASTIM MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 324. INDIA PEGFILGRASTIM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 325. INDIA PEGFILGRASTIM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 326. INDIA PEGFILGRASTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 327. INDIA PEGFILGRASTIM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 328. INDONESIA PEGFILGRASTIM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 329. INDONESIA PEGFILGRASTIM MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 330. INDONESIA PEGFILGRASTIM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 331. INDONESIA PEGFILGRASTIM MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 332. INDONESIA PEGFILGRASTIM MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 333. INDONESIA PEGFILGRASTIM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 334. INDONESIA PEGFILGRASTIM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 335. INDONESIA PEGFILGRASTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 336. INDONESIA PEGFILGRASTIM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 337. MALAYSIA PEGFILGRASTIM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 338. MALAYSIA PEGFILGRASTIM MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 339. MALAYSIA PEGFILGRASTIM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 340. MALAYSIA PEGFILGRASTIM MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 341. MALAYSIA PEGFILGRASTIM MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 342. MALAYSIA PEGFILGRASTIM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 343. MALAYSIA PEGFILGRASTIM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 344. MALAYSIA PEGFILGRASTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 345. MALAYSIA PEGFILGRASTIM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 346. AUSTRALIA PEGFILGRASTIM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 347. AUSTRALIA PEGFILGRASTIM MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 348. AUSTRALIA PEGFILGRASTIM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 349. AUSTRALIA PEGFILGRASTIM MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 350. AUSTRALIA PEGFILGRASTIM MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 351. AUSTRALIA PEGFILGRASTIM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 352. AUSTRALIA PEGFILGRASTIM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 353. AUSTRALIA PEGFILGRASTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 354. AUSTRALIA PEGFILGRASTIM MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 355. SOUTH KOREA PEGFILGRASTIM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 356. SOUTH KOREA PEGFILGRASTIM MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2030 (USD MILLION)
TABLE 357. SOUTH KOREA PEGFILGRASTIM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 358. SOUTH KOREA PEGFILGRASTIM MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
TABLE 359. SOUTH KOREA PEGFILGRASTIM MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 360. SOUTH KOREA PEGFILGRASTIM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 361. SOUTH KOREA PEGFILGRASTIM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 362. SOUTH KOREA PEGFILGRASTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 363. SOUTH KORE

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Pegfilgrastim market report include:
  • Alvotech
  • Amgen Inc.
  • Apotex Inc.
  • Biocon Biologics Limited
  • CinnaGen Inc.
  • Coherus BioSciences, Inc.
  • CuraTeQ Biologics Pvt. Ltd. by Aurobindo Pharma Ltd.
  • Dr. Reddy’s Laboratories Ltd.
  • Fresenius Kabi USA, LLC
  • Gennova Biopharmaceuticals Limited.
  • Intas Pharmaceuticals Ltd.
  • Mundipharma International Limited
  • Mylan N.V. by Viatris Inc.
  • Pfizer Inc.
  • Qilu Pharmaceutical Co., Ltd.
  • Sandoz Inc. by Novartis AG
  • Stada Arzneimittel AG

Related Topics

Related Reports

Pegfilgrastim Biosimilars Market Report 2025 - Product Image

Pegfilgrastim Biosimilars Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Pegfilgrastim Biosimilars Market Report and Forecast 2023-2031 - Product Image

Pegfilgrastim Biosimilars Market Report and Forecast 2023-2031

  • Report
  • 147 Pages
  • Global
From
Chemotherapy Induced Neutropenia Market by Product Type (Eflapegrastim, Filgrastim, Lipegfilgrastim), Therapy (Prophylaxis, Treatment), Route Of Administration, End User, Distribution Channel, Treatment Setting, Patient Group, Dosage Strength - Global Forecast 2025-2030 - Product Image

Chemotherapy Induced Neutropenia Market by Product Type (Eflapegrastim, Filgrastim, Lipegfilgrastim), Therapy (Prophylaxis, Treatment), Route Of Administration, End User, Distribution Channel, Treatment Setting, Patient Group, Dosage Strength - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From
Cancer Supportive Care Drugs Market by Drug Class, Indication, Distribution Channel, End User, Route Of Administration - Global Forecast 2025-2030 - Product Image

Cancer Supportive Care Drugs Market by Drug Class, Indication, Distribution Channel, End User, Route Of Administration - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
Chemotherapy-Induced Neutropenia Treatment Global Market Report 2025 - Product Image

Chemotherapy-Induced Neutropenia Treatment Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.